Brian Claggett
Brian Claggett
Harvard Medical School
確認したメール アドレス: partners.org
タイトル
引用先
引用先
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
MA Pfeffer, B Claggett, R Diaz, K Dickstein, HC Gerstein, LV Køber, ...
New England Journal of Medicine 373 (23), 2247-2257, 2015
14472015
Spironolactone for heart failure with preserved ejection fraction
B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ...
N Engl J Med 370, 1383-1392, 2014
13392014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
MA Pfeffer, B Claggett, SF Assmann, R Boineau, IS Anand, N Clausell, ...
Circulation 131 (1), 34-42, 2015
4982015
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction
E Kraigher-Krainer, AM Shah, DK Gupta, A Santos, B Claggett, B Pieske, ...
Journal of the American College of Cardiology 63 (5), 447-456, 2014
4502014
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis
H Uno, B Claggett, L Tian, E Inoue, P Gallo, T Miyata, D Schrag, ...
Journal of clinical Oncology 32 (22), 2380, 2014
2922014
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
AS Desai, JJV McMurray, M Packer, K Swedberg, JL Rouleau, F Chen, ...
European heart journal 36 (30), 1990-1997, 2015
2672015
Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ...
New England Journal of Medicine 381 (17), 1609-1620, 2019
2542019
Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone
AM Shah, B Claggett, NK Sweitzer, SJ Shah, IS Anand, L Liu, B Pitt, ...
Circulation 132 (5), 402-414, 2015
2122015
Declining risk of sudden death in heart failure
L Shen, PS Jhund, MC Petrie, BL Claggett, S Barlera, JGF Cleland, ...
New England Journal of Medicine 377 (1), 41-51, 2017
2022017
Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis
SB Seidelmann, B Claggett, S Cheng, M Henglin, A Shah, LM Steffen, ...
The Lancet Public Health 3 (9), e419-e428, 2018
2012018
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
SD Solomon, B Claggett, EF Lewis, A Desai, I Anand, NK Sweitzer, ...
European heart journal 37 (5), 455-462, 2016
1892016
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac …
AM Shah, B Claggett, NK Sweitzer, SJ Shah, IS Anand, E O’Meara, ...
Circulation: Heart Failure 7 (5), 740-751, 2014
1522014
Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure
MR Zile, BL Claggett, MF Prescott, JJV McMurray, M Packer, JL Rouleau, ...
Journal of the American College of Cardiology 68 (22), 2425-2436, 2016
1502016
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
JP Seferovic, B Claggett, SB Seidelmann, EW Seely, M Packer, MR Zile, ...
The lancet Diabetes & endocrinology 5 (5), 333-340, 2017
1442017
Impaired left atrial function in heart failure with preserved ejection fraction
ABS Santos, E Kraigher‐Krainer, DK Gupta, B Claggett, MR Zile, B Pieske, ...
European journal of heart failure 16 (10), 1096-1103, 2014
1352014
Spironolactone metabolites in TOPCAT—new insights into regional variation
S de Denus, E O’Meara, AS Desai, B Claggett, EF Lewis, G Leclair, ...
The New England journal of medicine 376 (17), 1690, 2017
1232017
Effectively selecting a target population for a future comparative study
L Zhao, L Tian, T Cai, B Claggett, LJ Wei
Journal of the American Statistical Association 108 (502), 527-539, 2013
1222013
Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
LH Lund, B Claggett, J Liu, CS Lam, PS Jhund, GM Rosano, K Swedberg, ...
European journal of heart failure 20 (8), 1230-1239, 2018
1202018
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
AA Voors, M Gori, LCY Liu, B Claggett, MR Zile, B Pieske, JJV McMurray, ...
European journal of heart failure 17 (5), 510-517, 2015
1182015
The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding
BH Hyett, MS Abougergi, JP Charpentier, NL Kumar, S Brozovic, ...
Gastrointestinal endoscopy 77 (4), 551-557, 2013
1172013
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20